Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brendan Guercio MD

Brendan J. Guercio MD

Assistant Professor of Medicine, University of Rochester Medical Center, Rochester, New York

Dr. Brendan Guercio is an Assistant Professor of Medicine at the Wilmot Cancer Center in Rochester, New York, and a Visiting Investigator at Memorial Sloan Kettering Cancer Center. He specializes in the care of patients with genitourinary malignancies.

Dr. Guercio completed his medical degree at Harvard Medical School and residency in internal medicine at Brigham & Women’s Hospital, where he also completed a Harvard Certificate of Biostatistics. He remained at Brigham & Women’s Hospital for one year as an attending hospitalist and instructor of medicine at Harvard Medical School prior to his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Guercio’s research focuses on clinical trials for novel therapies for genitourinary malignancies as well as predictive biomarkers such as circulating tumor DNA and the microbiome. Dr. Guercio has received Young Investigator Awards from the Bladder Cancer Advocacy Network (BCAN) and ASCO Conquer Cancer Foundation and has also been a recipient of research support from the NIH/NCI.

Disclosures

Dr. Guercio has previously received honoraria from Medscape and has been involved in studies with institutional research funding from Bristol-Myers Squibb, Genentech, Eli Lilly, Pfizer, Sanofi, and Oncocyte. He has received personal expenses from Natera, EMD Serono, Seagen/Astellas, and Gilead.